Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEAN
NCT04770389Phase 2Completed
- Sponsor
- NewAmsterdam Pharma
- Start
- Feb 2021
- Primary completion
- May 2021
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of obicetrapib in dyslipidemia (4 arms), sponsored by NewAmsterdam Pharma. Primary endpoint: Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) at 8 weeks. Started Feb 2021; status: completed.
02
Drugs
obicetrapib
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT04770389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04770389.